To assess the potential relevance of this type of immunomodulatory NAb to clinical autoimmune diseases, the activity of the PC-specific IgM–NAb was also tested in a system in which inflammatory responses are induced by lupus IgG autoantibodies (Vas et al., 2012). This evidence concerns the gene CD40LG and autoimmune disease.